Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | BI 907828 |
Synonyms | |
Therapy Description |
BI 907828 is MDM2 inhibitor that potentially inhibits tumor growth and improves anti-tumor immunity (PMID: 31201607; Cancer Res 2018;78(13 Suppl):Abstract nr 4866). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BI 907828 | BI907828|BI-907828 | MDM2 Inhibitor 20 | BI 907828 is an MDM2 inhibitor that potentially inhibits tumor growth and improves anti-tumor immunity (PMID: 31201607; Cancer Res 2018;78(13 Suppl):Abstract nr 4866). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03964233 | Phase I | BI 754091 + BI 754111 + BI 907828 BI 754091 + BI 907828 BI 907828 | A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab) | Recruiting | USA | 1 |
NCT03449381 | Phase I | BI 907828 | This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors) | Recruiting | USA | ESP | DEU | CAN | BEL | 2 |
NCT05218499 | Phase II | BI 907828 Doxorubicin | Brightline-1: A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma | Recruiting | ESP | CAN | BEL | 1 |